BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Cidara Therapeutics Inc.

Headquarters: San Diego, CA, United States
Year Founded: 2012
Status: Public
Industry Sector: HealthTechnology
CEO: Jeffrey L. Stein, PhD
Number Of Employees: 38
Enterprise Value: $-21,922,919
PE Ratio: -0.67
Exchange/Ticker 1: NASDAQ:CDTX
Exchange/Ticker 2: N/A
Latest Market Cap: $252,003,200

BioCentury | May 1, 2025
Management Tracks

Augustine follows up venture round with pair of C-suite hires

Plus: Management changes at Cidara, Fujifilm Cellular Dynamics and Transneural
BioCentury | Apr 5, 2025
Discovery & Translation

Science Spotlight: A FOXP3 regulator to enhance induced Tregs

BioCentury’s roundup of translational innovations also includes insights into high-fat diet disruption of feeding motivation; ER-targeted antigens; and more
BioCentury | Mar 25, 2025
Management Tracks

Warp Speed veteran Hepburn named EVP of R&D at Panther

Plus: Elicio names Preetam Shah CFO and chief strategy officer, and updates from Halozyme, Newron and Skye
BioCentury | Feb 20, 2025
Management Tracks

Bourla becomes chair of PhRMA

Plus: Steve Worland named CEO of Atomwise and updates from Ona, Cidara and Biosion
BioCentury | Jan 11, 2025
Management Tracks

Faces in new places ahead of JPM: Rubin joining Guggenheim

Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
BioCentury | Jan 9, 2025
Management Tracks

Bayer vet Moeller to lead Antag

Plus: CMO changes at Sunbird and Cidara, and updates from Aicuris, Renovaro, Noema and more
BioCentury | Nov 23, 2024
Finance

ATB’s €54M series A among largest ever in Belgium

BioCentury’s Financial Report also includes new biotech foundry Jupiter, and public equity fundings for Spyre, Cidara and Aclaris
BioCentury | Nov 20, 2024
Product Development

Biotechs now match pharma for FDA approvals

Half of FDA approvals are sponsored by biotechs; almost all are marketing in the U.S. themselves
BioCentury | Oct 19, 2024
Finance

Biotech restructurings show signs of slowing

Temporary respite or reflection of a stabilizing sector?
BioCentury | Aug 20, 2024
Management Tracks

Toraishi steps down from Rakuten Medical as co-CEO

Plus: SalioGen hired Kalliopi Stasi as CMO and updates from PepGen, Cidara and Bio-Rad
Items per page:
1 - 10 of 60